Back to Journals » Drug, Healthcare and Patient Safety » Volume 5

Update on the safety and bioequivalence of biosimilars – focus on enoxaparin

Authors Jeske W, Walenga JM, Hoppensteadt, Fareed J

Received 12 March 2013

Accepted for publication 24 April 2013

Published 10 June 2013 Volume 2013:5 Pages 133—141

DOI https://doi.org/10.2147/DHPS.S28813

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2


Walter Jeske,1 Jeanine M Walenga,1 Debra Hoppensteadt,2 Jawed Fareed2

1Cardiovascular Institute; 2Department of Pathology, Loyola University Chicago, Maywood, IL, USA

Abstract: Generic forms of chemically-derived drugs must exhibit chemical identity and be bioequivalent in healthy human subjects. The use of generic drugs results in a considerable savings of healthcare expenditures. Biologic drugs are produced in living systems or are derived from biologic material and extend beyond proteins to include antibodies, polysaccharides, polynucleotides, and live viral material. Such drugs pose a challenge to characterize as they tend to be larger in size than chemically-derived drugs, can exhibit a variety of post-translational modifications, and can have activities that are dependent on specific conformations. Biosimilars are not true generics, but rather, exhibit a high degree of similarity to the reference product and are considered to be biologically and clinically comparable to the innovator product. Therefore, the development process for biosimilars is more complex than for a true generic. Guidance is now available from the US Food and Drug Administration and from the European Medicines Agency for the development of biosimilar drugs. Biosimilar drugs are expected to have a major impact in the management of various diseases in coming years.

Keywords: generic, biosimilar, low molecular weight heparin

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]